Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
Grant Source:
NIH/NIAID 5R01AI120748-02; Marc M. Baum (PI); 06/26/15 - 05/31/20
Health Topics:
HIV
Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01)
Grant Source:
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from single institutions, or consortia of institutions, to identify existing anti-HIV molecules...
Health Topics:
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)
Grant Source:
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention.
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges
Date:
3/21/16
Citation:
Kovarova M, Swanson MD, Sanchez RI, et al. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21. PMID: 27002074; PMCID: PMC4867102.
Objectives:
Pre-exposure prophylaxis (PrEP) using antiretroviral drugs (ARVs) has been shown to reduce HIV transmission in people at high risk of HIV infection. Adherence to PrEP strongly correlates with the level of HIV protection. Long-acting injectable ARVs provide sustained systemic drug exposures over many weeks and can improve adherence due to infrequent parenteral administration. Here, we evaluated a new long-acting formulation of raltegravir for prevention of vaginal HIV transmission.
Health Topics:
Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment
Date:
3/20/16
Citation:
Ogunwuyi O, Kumari N, Smith KA, et al. Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment. Infect Dis (Auckl). 2016;9:21-32. Published 2016 Mar 20. doi:10.4137/IDRT.S38108. PMID: 27013886; PMCID: PMC4803317.
Highly active antiretroviral (ARV) therapy (HAART) for chronic suppression of HIV replication has revolutionized the treatment of HIV/AIDS. HAART is no panacea; treatments must be maintained for life. Although great progress has been made in ARV therapy, HIV continues to replicate in anatomical and intracellular sites where ARV drugs have restricted access.
Health Topics:
NIAID ChemDB HIV, Opportunistic Infection and Tuberculosis Therapeutics Database
This database contains information extracted from scientific literature on the structure and activity of compounds that have been tested against HIV, HIV enzymes or opportunistic pathogens.
Health Topics:
NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence
Grant Source:
NIH/NIMH 2 P01 DA028555; Howard Gendelman (PI); 07/01/15 – 06/30/20
Health Topics:
Towards Complete Sustained Release Nanoformulations of NRTI Based Regimens
Grant Source:
NIH/NIAID R01 AI114405; Caren Freel-Meyers (PI); 07/15/14 – 06/30/18
Health Topics:
Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program
Grant Source:
NIH/NIAID UM1 AI120176; Rodney Ho, PI; 08/01/2015 – 07/31/20
Health Topics: